Implantation of the CARMAT Heart in a 3rd Patient at the Georges Pompidou European Hospital

PARIS--(BUSINESS WIRE)--

Regulatory News:

CARMAT (Paris: ALCAR) (FR0010907956, ALCAR, PEA-PME eligible), the designer and developer of the world's most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage heart failure, today confirms the implantation of the CARMAT bioprosthesis in a 3rd patient.

This 3rd implantation of the CARMAT heart was carried out on April 8th by the Georges Pompidou European Hospital team (“Hôpital européen Georges Pompidou – Assistance Publique-Hôpitaux de Paris”) and went smoothly.

The feasibility study is scheduled to include a total of four patients suffering from irreversible bi-ventricular heart failure who are in an immediate life-threatening situation.

The criteria for success notably include the patient’s 30-day survival following the implant and the functional recovery of their vital organs.

Marcello Conviti, Chief Executive Officer of CARMAT, says: “We would like to congratulate the entire Georges Pompidou European Hospital team for again proving their medical prowess by carrying out the implantation of a 3rd CARMAT heart in a human. We are also very pleased with the state of health of the 2nd patient, who is now enjoying a normal life again after returning home at the beginning of the year.”

The Company would like to remind readers that, in accordance with good clinical practice and subject to regulatory obligations or specific circumstances, it is not planning to publish any information on the interim results of this ongoing feasibility study.

●●●

About CARMAT: the world’s most advanced total artificial heart project

A credible response to end-stage heart failure: CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world’s leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of Airbus Group, world aerospace leader.

Imitating the natural heart: given its size, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming the necessary clinical trials are successful, potentially benefit the lives of thousands of patients a year with no risk of rejection and with a good quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

Strongly committed, prestigious founders and shareholders: Airbus Group, Professor Alain Carpentier, the Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading European venture capital firm, and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

For more information: www.carmatsa.com

●●●

DisclaimerThis press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward‐looking statements that relate to the Company’s objectives. Such forward‐looking statements are based solely on the current expectations and assumptions of the Company’s management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company’s objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence filed with the Autorité des Marchés Financiers under number D.15-0138 on March 16, 2015, changes in economic conditions, the financial markets or the markets in which CARMAT operates. In particular, no guarantee can be given concerning the Company’s ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark. CARMAT products are currently exclusively used within the framework of clinical trials. They are not available outside these trials or for sale.

Name: CARMATISIN code: FR0010907956Ticker: ALCAR

CARMAT
Marcello Conviti
CEO
Patrick Coulombier
COO
Investor Relations
Tel.: +33 (0)1 39 45 64 50
[email protected]
or
Alize RP
Press Relations
Caroline Carmagnol
Tel.: +33 (0)1 44 54 36 66
[email protected]
or
NewCap
Financial Communication
and Investor Relations
Dusan Oresansky
Emmanuel Huynh
Tel.: +33 (0)1 44 71 94 94
[email protected]

Source: CARMAT

You May Also Be Interested In

• New Product Safety Recalls
• Snowline Gold Completes Oversubscribed C$31.9 Million Financing
• CPSC Warns Consumers to Stop Using Montebello ST and DRT63ST Gas Fireplaces; Multiple Fires Reported